Literature DB >> 16973741

A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis.

Sandra Muschiol1, Leslie Bailey, Asa Gylfe, Charlotta Sundin, Kjell Hultenby, Sven Bergström, Mikael Elofsson, Hans Wolf-Watz, Staffan Normark, Birgitta Henriques-Normark.   

Abstract

The intracellular pathogen Chlamydia trachomatis possesses a type III secretion (TTS) system believed to deliver a series of effector proteins into the inclusion membrane (Inc-proteins) as well as into the host cytosol with perceived consequences for the pathogenicity of this common venereal pathogen. Recently, small molecules were shown to block the TTS system of Yersinia pseudotuberculosis. Here, we show that one of these compounds, INP0400, inhibits intracellular replication and infectivity of C. trachomatis at micromolar concentrations resulting in small inclusion bodies frequently containing only one or a few reticulate bodies (RBs). INP0400, at high concentration, given at the time of infection, partially blocked entry of elementary bodies into host cells. Early treatment inhibited the localization of the mammalian protein 14-3-3beta to the inclusions, indicative of absence of the early induced TTS effector IncG from the inclusion membrane. Treatment with INP0400 during chlamydial mid-cycle prevented secretion of the TTS effector IncA and homotypic vesicular fusions mediated by this protein. INP0400 given during the late phase resulted in the detachment of RBs from the inclusion membrane concomitant with an inhibition of RB to elementary body conversion causing a marked decrease in infectivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973741      PMCID: PMC1566191          DOI: 10.1073/pnas.0606412103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Proteins in the chlamydial inclusion membrane.

Authors:  Daniel D Rockey; Marci A Scidmore; John P Bannantine; Wendy J Brown
Journal:  Microbes Infect       Date:  2002-03       Impact factor: 2.700

2.  CADD, a Chlamydia protein that interacts with death receptors.

Authors:  Frank Stenner-Liewen; Heike Liewen; Juan M Zapata; Krzysztof Pawlowski; Adam Godzik; John C Reed
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

3.  CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis.

Authors:  S P Fling; R A Sutherland; L N Steele; B Hess; S E D'Orazio; J Maisonneuve; M F Lampe; P Probst; M N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

4.  Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.

Authors:  Anna M Kauppi; Roland Nordfelth; Hanna Uvell; Hans Wolf-Watz; Mikael Elofsson
Journal:  Chem Biol       Date:  2003-03

5.  Mammalian 14-3-3beta associates with the Chlamydia trachomatis inclusion membrane via its interaction with IncG.

Authors:  M A Scidmore; T Hackstadt
Journal:  Mol Microbiol       Date:  2001-03       Impact factor: 3.501

6.  Evidence for the secretion of Chlamydia trachomatis CopN by a type III secretion mechanism.

Authors:  K A Fields; T Hackstadt
Journal:  Mol Microbiol       Date:  2000-12       Impact factor: 3.501

7.  Diversity within inc genes of clinical Chlamydia trachomatis variant isolates that occupy non-fusogenic inclusions.

Authors:  Daniel D Rockey; Wasna Viratyosin; John P Bannantine; Robert J Suchland; Walter E Stamm
Journal:  Microbiology       Date:  2002-08       Impact factor: 2.777

8.  A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin.

Authors:  D R Clifton; K A Fields; S S Grieshaber; C A Dooley; E R Fischer; D J Mead; R A Carabeo; T Hackstadt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-15       Impact factor: 11.205

9.  Chlamydia trachomatis interrupts an exocytic pathway to acquire endogenously synthesized sphingomyelin in transit from the Golgi apparatus to the plasma membrane.

Authors:  T Hackstadt; D D Rockey; R A Heinzen; M A Scidmore
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

10.  Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors.

Authors:  G Zhong; P Fan; H Ji; F Dong; Y Huang
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  83 in total

1.  Storage of platelets: effects associated with high platelet content in platelet storage containers.

Authors:  Hans Gulliksson; Per Sandgren; Agneta Sjödin; Kjell Hultenby
Journal:  Blood Transfus       Date:  2012-01-24       Impact factor: 3.443

Review 2.  Computational prediction of type III and IV secreted effectors in gram-negative bacteria.

Authors:  Jason E McDermott; Abigail Corrigan; Elena Peterson; Christopher Oehmen; George Niemann; Eric D Cambronne; Danna Sharp; Joshua N Adkins; Ram Samudrala; Fred Heffron
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

3.  Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Authors:  Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

4.  A multi-pronged search for a common structural motif in the secretion signal of Salmonella enterica serovar Typhimurium type III effector proteins.

Authors:  Garry W Buchko; George Niemann; Erin S Baker; Mikhail E Belov; Richard D Smith; Fred Heffron; Joshua N Adkins; Jason E McDermott
Journal:  Mol Biosyst       Date:  2010-09-29

5.  A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice.

Authors:  Jie Wang; Lili Chen; Fan Chen; Xiaoyun Zhang; Yingqian Zhang; Joel Baseman; Sondra Perdue; I-Tien Yeh; Rochelle Shain; Martin Holland; Robin Bailey; David Mabey; Ping Yu; Guangming Zhong
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

Review 6.  The biology and future prospects of antivirulence therapies.

Authors:  Lynette Cegelski; Garland R Marshall; Gary R Eldridge; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

7.  Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

Authors:  Anatoly Slepenkin; Per-Anders Enquist; Ulrik Hägglund; Luis M de la Maza; Mikael Elofsson; Ellena M Peterson
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

8.  Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Authors:  Jianfang Li; Chao Lv; Weiyang Sun; Zhenyu Li; Xiaowei Han; Yaoyao Li; Yuemao Shen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 9.  Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target.

Authors:  Alyssa C Fasciano; Lamyaa Shaban; Joan Mecsas
Journal:  EcoSal Plus       Date:  2019-02

Review 10.  Using small molecules to dissect mechanisms of microbial pathogenesis.

Authors:  Aaron W Puri; Matthew Bogyo
Journal:  ACS Chem Biol       Date:  2009-08-21       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.